Simple Summary Multiple Myeloma (MM) is a hematologic malignancy caused by aberrant
plasma cell proliferation in the bone marrow (BM) and constitutes the second most common …

Avoiding immune destruction is a hallmark of cancer. Over the past few years, significant
advances have been made in understanding immune dysfunction and immunosuppression …

A majority of human papillomavirus (HPV) infections are asymptomatic and self-resolving in
the absence of medical interventions. Various innate and adaptive immune responses, as …

IDO1 (indoleamine 2, 3-dioxygenase 1) is a member of a unique class of mammalian haem
dioxygenases that catalyse the oxidative catabolism of the least-abundant essential amino …

Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow (BM) and represents
the second most common hematological malignancy in the world. The MM tumor …

Extramedullary multiple myeloma (EMM) can present either at initial diagnosis (de novo) or
at disease relapse (secondary) and confers an aggressive clinical course. Limited data exist …

The imbalance of immune status in cancer microenvironment plays an important role in the
development and progression of cancer. Immunotherapy based on this has become an …

An overactivation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor
(MET) axis promotes tumorigenesis and tumor progression in various cancer types …

Multiple myeloma (MM) is a clonal plasma cell malignancy affecting a predominantly elderly
population. The continued development of newer therapies with novel mechanisms of action …

BACKGROUND Patients hospitalized for COVID-19 exhibit diverse clinical outcomes, with
outcomes for some individuals diverging over time even though their initial disease severity …